Adding IV ferric carboxymaltose to traditional standard therapy can improve outcomes for patients with heart failure (HF) with reduced ejection fraction and iron deficiency, according to results from the AFFIRM-AHF trial.
In patients with iron deficiency and a left ventricular ejection fraction of less than 50% who were stabilized after an episode of acute HF, treatment with ferric carboxymaltose (Injectafer, American Regent) was safe and reduced the risk for heart failure